智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司瑞石生物医药有限公司收到国家 药品监督管理局(简称"国家药监局")核准签发关于RSS0393软膏的《药物临床试验批准通知书》，将于 近期开展临床试验。 SS0393软膏是公司自主研发的含PDE4小分子抑制剂的软膏，涂抹后可通过抑制多种细胞内的PDE4活 性，缓解组织损伤和炎症。 ...

恒瑞医药9月4日公告，公司及子公司福建盛迪医药有限公司收到国家药监局核准签发关于HRS-4729注 射液的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-4729注射液是公司自主研发的多 肽类药物，是一种胰高血糖素样肽-1受体（GLP-1R）/葡萄糖依赖性促胰岛素多肽受体（GIPR）/胰高 血糖素受体（GCGR）三激动剂。与GLP-1R/GIPR双靶点相比，三重受体激动剂通过在体内调节糖脂代 谢、抑制食欲的基础上增加GCGR靶点激活活性，促进能量消耗、脂肪酸氧化、脂质分解，从而更好地 发挥减重和减少肝脏脂肪效果。 ...

恒瑞医药9月4日公告，子公司瑞石生物医药有限公司收到国家药监局核准签发关于RSS0393软膏的《药 物临床试验批准通知书》，将于近期开展临床试验。RSS0393软膏是公司自主研发的含PDE4小分子抑 制剂的软膏，涂抹后可通过抑制多种细胞内的PDE4活性，缓解组织损伤和炎症。 ...

Group 1: Overview of China's Biomanufacturing Industry - The value added by the biomanufacturing sector accounts for over 7% of China's GDP [4] - China ranks second globally in the number of CAR-T cell therapy research centers and the number of biopharmaceuticals under research [1][4] - The biopharmaceutical market in China has surpassed 1.1 trillion yuan, with a significant number of innovative drugs and research pipelines [5] Group 2: Innovations and Developments - The "National Innovation Drug Insight System" was launched to enhance the efficiency of innovative drug development and address industry challenges [7] - The Hubei Pathology Big Database has reached 170,000 high-precision digital slices, positioning it as the second largest globally [6] - The global CAR-T clinical research centers have increased by 60% from 2020 to 2024, with China contributing 388 centers [5] Group 3: Market Growth and Future Projections - The global biomanufacturing market is projected to grow significantly, with the biobased chemicals market expected to reach $125.23 billion by 2029 [8] - China's biomanufacturing sector is positioned as a new engine for economic growth, supported by national policies and strategic planning [8] - The biotechnological innovations in agriculture, such as genetically modified crops, are set to enter the industrialization demonstration phase in 2024 [9]

Core Viewpoint - The AI Fund Guotou UBS Innovative Medical Mixed A (005520) reported a profit of 9.4516 million yuan for the first half of 2025, with a net value growth rate of 20.2% and a fund size of 55.1318 million yuan as of the end of June 2025 [2][31]. Fund Performance - As of September 3, 2025, the fund's one-year cumulative net value growth rate reached 67.54%, ranking 58 out of 136 comparable funds [5]. - The fund's net value growth rates for the past three months and six months were 32.25% and 50.66%, respectively, ranking 34 out of 138 and 52 out of 138 among comparable funds [5]. Investment Strategy - The fund manager expressed optimism about the long-term potential of the innovative drug sector, focusing on companies with certainty and reasonable valuations for long-term holdings [2]. - The fund also maintains a positive outlook on the CXO/research service sector, anticipating continued demand improvement and favorable conditions for investment and financing as the Federal Reserve gradually lowers interest rates [2]. Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 44.55 times, significantly lower than the industry average of 120.96 times [10]. - The weighted average price-to-book (P/B) ratio was about 3.27 times, compared to the industry average of 4.07 times, and the weighted average price-to-sales (P/S) ratio was approximately 4.27 times, against an industry average of 6.52 times [10]. Growth Metrics - For the first half of 2025, the fund's weighted average revenue growth rate was 0.06%, and the weighted average net profit growth rate was 0.52% [17]. - The weighted annualized return on equity was recorded at 0.07% [17]. Fund Composition - As of June 30, 2025, the fund held a total of 4,131 investors, with a total of 58.9068 million units held [34]. - The top ten holdings included companies such as Heng Rui Pharmaceutical, Kelun-Botai Biological, and Innovent Biologics [39].

格隆汇9月4日｜恒瑞医药公告，公司于2025年9月4日首次回购A股股份27万股，占公司总股本的 0.004%，成交价格在67.75元/股至67.97元/股之间，累计已支付总金额为1831.39万元。此次回购用于实 施A股员工持股计划，回购价格不超过90.85元/股，预计金额在10亿元至20亿元之间。 ...

Group 1 - The launch of the Hong Kong and US stock performance meeting roadshow channel by Panorama Network provides a new platform for Chinese companies to communicate with global investors, enhancing the globalization of Chinese enterprises [1][4] - The China Securities Regulatory Commission has introduced five measures to support leading domestic companies in listing and financing in Hong Kong, significantly boosting the activity of the Hong Kong market as a bridge for mainland enterprises to "go global" [2][3] - The Hang Seng Index has shown a year-to-date increase of 27.10% as of September 2, 2025, indicating enhanced market confidence and sustained capital inflow [2] Group 2 - The IPO market in Hong Kong has performed exceptionally well, with total fundraising reaching 138.275 billion HKD as of September 2, 2025, surpassing the total for the entire year of 2024 [2][3] - Notable companies such as CATL and Heng Rui Pharmaceutical have emphasized internationalization as a strategic focus, with CATL planning to allocate approximately 90% of its raised funds for projects in Hungary [3] - The US stock market has shown steady performance, with the Nasdaq index increasing by 10.20% year-to-date as of September 2, 2025, driven by the technology sector [3] Group 3 - The Panorama Network's new channel allows investors to access real-time performance explanations, strategic interpretations, and major updates from Chinese companies listed overseas, thereby reducing information asymmetry and improving decision-making quality [4][6] - Since 2017, the Hong Kong Stock Exchange has utilized Panorama Network for live broadcasts of annual and interim performance meetings, completing 12 roadshows to date [4] - The Panorama Network has established a strong market presence, with over 3,500 listed companies on its service platform, achieving a market coverage rate of 66% [5]

Group 1 - The top three AH premium rates are held by Northeast Electric (800.00%), Fudan Zhangjiang (245.38%), and Andeli Juice (241.51%) [1][2] - The bottom three AH premium rates are recorded by Ningde Times (-13.29%), Hengrui Medicine (6.01%), and Zijin Mining (8.06%) [1][2] - Fudan Zhangjiang, Dongjiang Environmental Protection, and Jinli Permanent Magnet have the highest deviation values at 30.70%, 24.70%, and 23.97% respectively [1][2] Group 2 - The top ten AH stocks by premium rate include companies like Northeast Electric, Fudan Zhangjiang, and Andeli Juice, with premium rates exceeding 200% [2] - The bottom ten AH stocks by premium rate include Ningde Times, Hengrui Medicine, and Zijin Mining, with premium rates below 10% [2] - The deviation values for the top ten AH stocks show significant discrepancies, with Fudan Zhangjiang leading at 30.70% [3]

来源：滚动播报 香港恒生指数收跌1.12%，恒生科技指数跌1.85%。芯片股普跌，中芯国际、上海复旦跌超6%，华虹半 导体跌超5%；创新药概念股回调，歌礼制药跌超10%，恒瑞医药跌超6%；黄金板块下跌，灵宝黄金、 中国黄金国际跌超7%。 ...

Core Insights - Long-term institutional investors are revealing their holdings while the market debates short-term volatility [2][18] - Fund managers like Zhang Kun and Ge Lan are making strategic adjustments in their portfolios, indicating their market outlook [2][9] Fund Manager Strategies - Zhang Kun has expressed skepticism about the pessimistic expectations for domestic demand, suggesting that consumer confidence is influenced by income expectations and social security systems [16][17] - Ge Lan is focusing on innovative pharmaceuticals and medical devices, anticipating growth driven by innovation and consumer recovery [17] Portfolio Adjustments - Zhang Kun's fund, E Fund Blue Chip Select, has reduced its stock position slightly, with the top ten holdings now accounting for 83.84% of the fund's net value, the highest in ten quarters [3][4] - The fund has introduced new holdings such as Beike-W and Chao Yan Technology, while previously held stocks like Newell and Mindray Medical have been removed [4][7] Hidden Holdings - The "invisible heavyweights" in Zhang Kun's portfolio include stocks like Focus Media, Meituan-W, and Hong Kong Exchanges, with significant changes in their holdings [4][5] - Ge Lan's hidden holdings also feature stocks like Huadong Medicine and Hualan Biological Engineering, reflecting her focus on the pharmaceutical sector [10][12] Market Performance - The stocks in these funds have generally supported the funds' net value increases, with some stocks experiencing significant price rises since July [14] - The overall market sentiment remains cautious, but long-term investors see opportunities to acquire high-quality stocks at lower valuations [17]